MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412177 | Name: 502U83

Description:

WARNING: This product is for research use only, not for human or veterinary use.

502U83 is an arylmethylaminopropanediol that displays significant antitumor activity in a number of murine and human tumor-model systems

Chemical Structure

502U83
502U83
CAS#129026-48-8

Theoretical Analysis

MedKoo Cat#: 412177

Name: 502U83

CAS#: 129026-48-8

Chemical Formula: C21H25NO4

Exact Mass: 355.1784

Molecular Weight: 355.43

Elemental Analysis: C, 70.96; H, 7.09; N, 3.94; O, 18.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
502U83; BW502U83; BW-502U83 BW 502U83
IUPAC/Chemical Name
1,3-Propanediol, 2-(((10-(2-hydroxyethoxy)-9-anthracenyl)methyl)amino)-2-methyl-
InChi Key
InChI=1S/C21H25NO4/c1-21(13-24,14-25)22-12-19-15-6-2-4-8-17(15)20(26-11-10-23)18-9-5-3-7-16(18)19/h2-9,22-25H,10-14H2,1H3
InChi Code
SMILES Code
OCC(C)(NCC1=C2C=CC=CC2=C(OCCO)C3=CC=CC=C13)CO
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 355.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dorr RT, Bellamy W, Liddil JD, Baker A, Bair KW. Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998 Oct;13(7):825-35. PMID: 9807165. 2: van der Graaf WT, Zijlstra JG, de Vries EG, Nethersell AB, Mulder NH. In vitro and in vivo studies on the action of BW502U83, an arylmethylaminopropanediol. Anticancer Drugs. 1995 Feb;6(1):34-9. doi: 10.1097/00001813-199502000-00003. PMID: 7756681. 3: Schilsky RL, Ratain MJ, Janisch L, Vogelzang NJ, Lucas VS, Ravitch J, Hohneker JA, Clendeninn NJ, Tuttle RL. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993;31(4):283-8. doi: 10.1007/BF00685672. PMID: 8422691. 4: Patel DK, Lewis RP, Hinton ML, Schroeder DH, Shockcor JP, Johnson RL, Sigel CW. Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83. Drug Metab Dispos. 1993 Jan-Feb;21(1):62-70. PMID: 8095228. 5: Lam KS, Alberts DS, Peng YM, Brodar F, Matias B, Modiano M, Tuttle R, Sol Lucas V, Wargin W. Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients. Anticancer Drugs. 1992 Jun;3(3):219-24. doi: 10.1097/00001813-199206000-00003. PMID: 1525401. 6: Bair KW, Andrews CW, Tuttle RL, Knick VC, Cory M, McKee DD. 2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding. J Med Chem. 1991 Jul;34(7):1983-90. doi: 10.1021/jm00111a010. PMID: 2066971. 7: Carter CA, Bair KW. Effects of isomeric 2-(arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells. Invest New Drugs. 1991 May;9(2):125-36. doi: 10.1007/BF00175080. PMID: 1874597. 8: Von Hoff DD, Kuhn JG, Havlin KA, Langevin AM, Brown TD, Weiss GR, Turner JN, Purvis J, Lucas VS, Bair KW, et al. Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule. Cancer Res. 1990 Dec 1;50(23):7496-500. PMID: 2253197. 9: Bair KW, Tuttle RL, Knick VC, Cory M, McKee DD. (1-Pyrenylmethyl)amino alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies. J Med Chem. 1990 Sep;33(9):2385-93. doi: 10.1021/jm00171a012. PMID: 2391683.